Li Cheung

Dr. Li Cheung


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in The Lancet Oncology
Verified
Journal Article
Closed access
HKHormuzd A Katki
Hormuzd A Katki
WKWalter K Kinney
Walter K Kinney
BFBarbara Fetterman
Barbara Fetterman
TLThomas Lorey
Thomas Lorey
NPNancy E Poitras
Nancy E Poitras
PCPhilip E Castle
Philip E Castle

15 July 2008 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
Gabriel ChodickGabriel Chodick
Gabriel Chodick
NBNural Bekiroglu
Nural Bekiroglu
MHMichael Hauptmann
Michael Hauptmann
BABruce H. Alexander
Bruce H. Alexander
DFD. Michal Freedman
D. Michal Freedman
ASAlice J. Sigurdson
Alice J. Sigurdson
The study aim was to determine the risk of cataract among radiologic technologists with respect to occupational and nonoccupational exposures to ionizing radiation and to personal characteristics. A prospective cohort of 35,705 cataract-free US radiologic technologists aged 24–44 years was followed for nearly 20 years (1983–2004) by using two follow-up questionnaires. During the study period, 2,382 cataracts and 647 cataract extractions were reported. Cigarette smoking for ≥5 pack-years; body mass index of ≥25 kg/m2; and history of diabetes, hypertension, hypercholesterolemia, or arthritis at baseline were significantly (p ≤ 0.05) associated with increased risk of cataract. In multivariate models, self-report of ≥3 x-rays to the face/neck was associated with a hazard ratio of cataract of 1.25 (95% confidence interval: 1.06, 1.47). For workers in the highest category (mean, 60 mGy) versus lowest category (mean, 5 mGy) of occupational dose to the lens of the eye, the adjusted hazard ratio of cataract was 1.18 (95% confidence interval: 0.99, 1.40). Findings challenge the National Council on Radiation Protection and International Commission on Radiological Protection assumptions that the lowest cumulative ionizing radiation dose to the lens of the eye that can produce a progressive cataract is approximately 2 Gy, and they support the hypothesis that the lowest cataractogenic dose in humans is substantially less than previously thought.

15 February 2010 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
ARAna Cecilia Rodríguez
Ana Cecilia Rodríguez
MSMark Schiffman
Mark Schiffman
RHRolando Herrero
Rolando Herrero
AHAllan Hildesheim
Allan Hildesheim
CBConcepción Bratti
Concepción Bratti
RBRobert D. Burk
Robert D. Burk
The natural history of human papillomavirus (HPV) infections in older women is critical for preventive strategies, including vaccination and screening intervals, but is poorly understood. In a 7-year population-based cohort study in Guanacaste, Costa Rica, we examined whether women’s age and the duration of carcinogenic HPV infections influenced subsequent persistence of infection and risk of cervical intraepithelial neoplasia grade 2 (CIN 2) or worse disease. At enrollment, of the 9466 participants eligible for pelvic examination, 9175 were screened for cervical neoplasia using multiple methods; those with CIN 2 or worse disease were censored and treated. Participants at low risk of CIN 2 or worse (n = 6029) were rescreened at 5–7 years (passively followed), whereas higher-risk participants (n = 2115) and subsets of low-risk women (n = 540) and initially sexually inactive women (n = 410) were rescreened annually or semiannually (actively followed) for up to 7 years. HPV testing was done using a polymerase chain reaction–based method. We determined, by four age groups (18–25, 26–33, 34–41, and ≥42 years), the proportion of prevalent infections (found at baseline) and newly detected infections (first found during follow-up) that persisted at successive 1-year time points and calculated absolute risks of CIN 2 and CIN grade 3 (CIN 3) or worse during follow-up. P values are two-sided. Regardless of the woman's age, newly detected infections were associated with very low absolute risks of persistence, CIN 2, or worse disease. For newly detected infections, the rate of progression to CIN 2+ (or CIN 3+), after 3 years of follow-up, was not higher for women aged 34 years and older than for younger women. Moreover, rates of newly detected infections declined sharply with age (in the actively followed group, at ages 18–25, 26–33, 34–41, and ≥42 years, rates were 35.9%, 30.6%, 18.1%, and 13.5%, respectively; P < .001). Among prevalent infections, persistent infections among older women (≥42 years) was higher than that among younger age groups or new infections at any age ( P < .01 for comparison of eight groups). Most (66 of 85) CIN 2 or worse detected during follow-up was associated with prevalent infections. Only a small subset (25 of 1128) of prevalent infections persisted throughout follow-up without apparent CIN 2 or worse. The rate of new infections declines with age, and new infections typically do not progress to CIN 2 or worse disease in older women; thus, overall potential benefit of prophylactic vaccination or frequent HPV screening to prevent or detect new carcinogenic HPV infections at older ages is low.

7 June 2016 in JAMA
Verified
Journal Article
Open access
PDF file
HKHormuzd A. Katki
Hormuzd A. Katki
SKStephanie A. Kovalchik
Stephanie A. Kovalchik
CBChristine D. Berg
Christine D. Berg
LCLi Cheung
Li Cheung
ACAnil K. Chaturvedi
Anil K. Chaturvedi
Lung cancer is the most common cause of cancer death in the United States.1 The National Lung Screening Trial (NLST) demonstrated a 20% reduction in lung cancer mortality with 3 rounds of low-dose computed tomography (CT) screening as compared with chest radiography, over a mean follow-up of 6.4 years.2 Consequently, the US Preventive Services Task Force (USPSTF) and the US Centers for Medicare & Medicaid Services now recommend annual CT screening for a risk factor–based subgroup of smokers—current and former smokers aged 55 to 80 years and 55 to 77 years, respectively, with at least 30 pack-years of smoking and, for former smokers, no more than 15 years since quitting.3,4 These were largely based on the entry criteria for the NLST as well as microsimulation models that considered subgroups defined by age, pack-year, and quit-year criteria.5,6

3 June 2014 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
JGJulia C. Gage
Julia C. Gage
MSMark Schiffman
Mark Schiffman
HKHormuzd A. Katki
Hormuzd A. Katki
PCPhilip E. Castle
Philip E. Castle
BFBarbara Fetterman
Barbara Fetterman
WKWalter K. Kinney
Walter K. Kinney
Primary human papillomavirus (HPV) testing (without concurrent Pap tests) every 3 years is under consideration in the United States as an alternative to the two recommended cervical cancer screening strategies: primary Pap testing every 3 years, or concurrent Pap and HPV testing (“cotesting”) every 5 years. Using logistic regression and Weibull survival models, we estimated and compared risks of cancer and cervical intraepithelial neoplasia grade 3 or worse (CIN3+) for the three strategies among 1011092 women aged 30 to 64 years testing HPV-negative and/or Pap-negative in routine screening at Kaiser Permanente Northern California since 2003. All statistical tests were two sided. Three-year risks following an HPV-negative result were lower than 3-year risks following a Pap-negative result (CIN3+ = 0.069% vs 0.19%, P < .0001; Cancer = 0.011% vs 0.020%, P < .0001) and 5-year risks following an HPV-negative/Pap-negative cotest (CIN3+ = 0.069% vs 0.11%, P < .0001; Cancer = 0.011% vs 0.014%, P = .21). These findings suggest that primary HPV testing merits consideration as another alternative for cervical screening.

1 April 2013 in Journal of Lower Genital Tract Disease
Verified
Journal Article
Closed access
HKHormuzd A. Katki
Hormuzd A. Katki
MSMark Schiffman
Mark Schiffman
PCPhilip E. Castle
Philip E. Castle
BFBarbara Sct (Ascp) Fetterman
Barbara Sct (Ascp) Fetterman
NPNancy E. Pmp Poitras
Nancy E. Pmp Poitras
WKWalter K. Kinney
Walter K. Kinney
Objective In 2012, the US Preventive Services Task Force (USPSTF) and a consensus of 25 organizations endorsed concurrent cytology and human papillomavirus (HPV) testing (“cotesting”) for cervical cancer screening. Past screening and management guidelines were implicitly based on risks defined by Pap-alone, without consideration of HPV test results. To promote management that is consistent with accepted practice, new guidelines incorporating cotesting should aim to achieve equal management of women at equal risk of cervical intraepithelial neoplasia grade 3 and cancer (CIN 3+). Methods We estimated cumulative 5-year risks of CIN 3+ for 965,360 women aged 30 to 64 years undergoing cotesting at Kaiser Permanente Northern California over 2003 to 2010. We calculated the implicit risk thresholds for Pap-alone and applied them for new management guidance on HPV and Pap cotesting, citing 2 examples: HPV-positive/atypical squamous cells of undetermined significance (ASC-US) and HPV-negative/Pap-negative. We call this guidance process “benchmarking.” Results A low-grade squamous intraepithelial lesion result, for which immediate colposcopy is prescribed, carries a 5-year CIN 3+ risk of 5.2%, suggesting that test results with similar risks should be managed with colposcopy. Similarly, ASC-US (2.6% risk) is managed with a 6- to 12-month follow-up visit and Pap-negative (0.26% risk) is managed with a 3-year follow-up visit. The 5-year CIN 3+ risk among women with HPV-positive/ASC-US was 6.8% (95% confidence interval = 6.2%–7.6%). This is greater than the 5.2% risk implicitly leading to referral for colposcopy, consistent with current management recommendations that women with HPV-positive/ASC-US be referred for immediate colposcopy. The 5-year CIN 3+ risk among women with HPV-negative/Pap-negative results was 0.08% (95% confidence interval = 0.07%–0.09%), far below the 0.26% implicitly required for a 3-year return and justifying a longer (e.g., 5-year) return. Conclusions Using the principle of “equal management of equal risks,” benchmarking to implicit risk thresholds based on Pap-alone can be used to achieve safe and consistent incorporation of cotesting.